Immune response to recombinant visna virus Gag and Env precursor proteins synthesized in insect cells

Rafnar, Björg; Tobin, Gregory J.; Nagashima, Kunio; Gonda, Matthew A.; Gunnarsson, Eggert; Andrésson, Ólafur S.; Georgsson, Guðmundur; Torsteinsdóttir, Sigurbjörg

doi:10.1016/s0168-1702(97)00141-x

Cited by 12 publications

(4 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is likely that the stability of the proteins is different. p25 is the major structural capsid protein which may self assemble into stable virus-like particles, and there is limited evidence for this with MVV capsid (50,51). Certainly from the bacterial expression data presented here, p25 was the easiest gag antigen to express and purify.…”

Section: Discussionmentioning

confidence: 84%

Immune Response to Individual Maedi-Visna VirusgagAntigens

Singh

McConnell

Blacklaws

2006

J Virol

View full text Add to dashboard Cite

The lesions caused by maedi-visna virus (MVV) are known to be immune mediated with a presumed contribution by the response to viral antigens. However, very little is known about the T-cell response to individual viral proteins. We have therefore expressed the three individual gag antigens of MVV strain EV1 (p16, p25, and p14) in a bacterial expression system and used the purified recombinant proteins to analyze the antibody and CD4؉ T-cell response to MVV. Plasma samples were taken from sheep after 1 year of infection with MVV. The titers for antibodies in these samples were determined by indirect enzyme-linked immunosorbent assays and were as follows: anti-p25 antibody, 1:400 to >1:3,200; anti-p16 antibody, 1:400 to 1:3,200; and anti-p14 antibody, 1:<100 to 1:3,200. When the induction of antibodies was followed over time postinfection (p.i.), samples positive for anti-p25 were seen by day 24 p.i., followed by anti-p16 by day 45 p.i., and lastly anti-p14 by day 100 p.i. T-cell proliferative responses to all three gag antigens were detected in persistently infected sheep peripheral blood lymphocytes. The antigens were therefore used to raise T-cell lines from persistently infected sheep. These T-cell lines were shown to be specific for the recombinant gag antigens and for viral antigen expressed on infected macrophages. The proliferative response was restricted to major histocompatibility complex class II HLA-DR and so was due to CD4 ؉ T lymphocytes. All three gag antigens may therefore play a role in immune-mediated lesion formation in MVV disease by presentation on infected macrophages in lesions.

show abstract

Section: Discussionmentioning

confidence: 84%

Immune Response to Individual Maedi-Visna VirusgagAntigens

Singh

McConnell

Blacklaws

2006

J Virol

View full text Add to dashboard Cite

show abstract

“…However, myristoylation is not required for MVV budding, and it is not clear whether the MVV Gag precursor requires alternative fatty acid modification (e.g. acetylation) or remains unmodified (Rafnar et al 1998). MVV Gag is processed to p16 (MA), p25 (CA) and p14 (NC) (Vigne et al 1982).…”

Section: Genes and Proteins Of Mvv And Hiv-1mentioning

confidence: 99%

Maedi-visna virus as a model for HIV

Andrésdóttir¹

2018

IAS

View full text Add to dashboard Cite

Maedi-visna virus (MVV) is a lentivirus of sheep causing inflammation in many organs, primarily the lungs and CNS. HIV and SIV also belong to the lentivirus genus of retroviruses. MVV and HIV have many features in common, including genome organization, mode of virus replication, virus-host interaction and latency. Both viruses infect cells of the monocyte/macrophage lineage, but the main difference in cell tropism is that, whereas HIV infects T lymphocytes, MVV does not. Here, the molecular biology, cell tropism and pathogenesis of MVV are reviewed and some of the similarities as well as the dissimilarities between MVV and HIV are discussed.

show abstract

“…The same antigens were used to raise T cell lines from persistently infected sheep that proliferated in response to viral antigens expressed by autologous macrophages (53). We have shown that sheep immunized either with the Gag precursor or the whole Env protein, expressed in insect cells, responded to whole virus in proliferation assay (105). In CAEV infected or vaccinated goats, virus specific CD4 T-lymphocytes have been shown to proliferate in response to CAEV antigens (89,106).…”

Section: Cellular Immunitymentioning

confidence: 99%

“…The Gag and the Env proteins produced in the Baculovirus system were used for immunization. The sheep developed high antibody titers in ELISA and a proliferative response to whole virus (105). They were challenged intravenously and virus was isolated from blood a few weeks after challenge.…”

Section: Vaccination Attemptsmentioning

confidence: 99%

Immune response to maedi-visna virus

Torsteinsdóttir

Andresdottir²,

Arnarson³

et al. 2007

Front Biosci

View full text Add to dashboard Cite

The ovine maedi-visna virus (MVV) was the first lentivirus to be isolated and characterized 1957 in Iceland. MVV leads to a life-long, persistent infection with slow development of lesions in the lung and the central nervous system (CNS). The main target cells of MVV are of the monocyte/macrophage lineage and it does not infect T-lymphocytes or cause immune suppression like human immune deficiency virus (HIV). In spite of a fairly good immune response, including both neutralizing antibodies and cytotoxic T lymphocytes, the virus persists in the host and establishes a life-long infection. There are strong indications that the pathological lesions are immune-mediated and vaccination attempts have not only failed to induce sterile immunity but have occasionally caused increased viremia and more severe disease.

show abstract

Immune response to recombinant visna virus Gag and Env precursor proteins synthesized in insect cells

Cited by 12 publications

References 44 publications

Immune Response to Individual Maedi-Visna VirusgagAntigens

Immune Response to Individual Maedi-Visna VirusgagAntigens

Maedi-visna virus as a model for HIV

Immune response to maedi-visna virus

Contact Info

Product

Resources

About